The Latest Breaking News from Solid Biosciences

Solid Biosciences' Duchenne muscular dystrophy (DMD) drug could provide superior outcomes compared to an already approved medication projected to make billions.

Solid Biosciences just saw a 32% move to the upside after its trial results impressed. What's next for this firm that analysts still see massive potential in?

Solid Biosciences (NASDAQ:SLDB) brought in sales totaling $1.93 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 36.1%, resulting in a loss of $25.33 million.

Solid Biosciences Inc (NASDAQ: SLDB) is shaving down its pipeline, updating its operations strategy to prioritize the advancement of AAV-mediated gene transfer therapies, SGT-001 and SGT-003.

  Solid Biosciences (NASDAQ:SLDB) reported its Q1 earnings results on Wednesday, April 27, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Solid Biosciences (NASDAQ:SLDB) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement. Analysts estimate that Solid Biosciences will report an earnings per share (EPS) of $-0.18.

Benzinga Pro data, Solid Biosciences (NASDAQ:SLDB) reported Q4 sales of $3.15 million. Earnings fell to a loss of $18.61 million, resulting in a 3.49% decrease from last quarter.

Solid Biosciences Inc (NASDAQ:SLDB) has reported two-year interim efficacy and safety data from the first three patients treated with SGT-001 in the high dose (2E14 vg/kg) cohort as part of IGNITE DMD.  Results suggest durable benefit 24-months post-administration of SGT-001 compared to natural history, consistent with results reported at the 12-month and 18-month…

  Solid Biosciences (NASDAQ:SLDB) reported its Q4 earnings results on Monday, March 14, 2022 at 06:00 AM. Here's what investors need to know about the announcement.